Pain management market seen reaching $139.8B by 2035

Market Research Future projects the global pain management market will grow from $91.82 billion in 2026 to $139.80 billion by 2035, driven by aging populations, chronic disease, and a shift away from opioid-centric care. The forecast points to faster growth in neuromodulation, digital therapeutics and non-narcotic options as payers and regulators push multimodal treatment.

Why it matters: - The pain management market is moving toward non-opioid and device-led care as health systems look for durable relief with fewer addiction risks. - The shift affects drugmakers, device companies, payers and providers across hospitals, ambulatory centers and home care. - Market Research Future projects the global market will rise to $139.80 billion by 2035 from $91.82 billion in 2026, with a 4.95% CAGR. - The market base was estimated at $87.65 billion in 2025.

What happened: - Market Research Future released a forecast for the global pain management market on June 11, 2026. - The report expects the market to expand steadily through 2035, powered by aging populations and a heavier chronic disease burden. - The report says the industry is shifting from opioid-centric care to multimodal analgesia, neuromodulation and digital therapeutics. - A free sample is available here.

The details: - The report ties growth to three main forces: an aging global population, regulatory pressure to reduce opioid use and new neuromodulation platforms. - The number of people over 60 is projected to reach 2.1 billion by 2050, about twice the 2020 level. - In the U.S., about 51 million adults live with chronic pain, creating annual economic costs of $560 billion to $635 billion. - Neuropathic pain is the largest application segment, supported by the global diabetes burden of more than 537 million adults. - Non-narcotic analgesics are gaining share as first-line options, including NSAIDs, acetaminophen combinations, CGRP inhibitors, gabapentinoids and SNRIs. - The devices segment is expanding as closed-loop spinal cord stimulators, dorsal root ganglion therapy and high-frequency stimulation gain traction. - Hospitals remain the largest care setting with about 66.8% of revenue in 2025. - Ambulatory surgical centers generated $12.40 billion in 2025. - Home care and other settings are the fastest-growing care setting, at 12.5% CAGR from 2026 to 2035. - Neuromodulation devices are the fastest-growing product segment, at 10.8% CAGR from 2026 to 2035. - Facial pain and migraine is the fastest-growing application segment, at 9.4% CAGR from 2026 to 2035. - Cancer pain accounted for $20.90 billion in 2025 and is projected to grow at 5.2% CAGR. - North America held about 35.4% of the market in 2025, while Asia-Pacific is the fastest-growing region at 11.5% CAGR. - Europe was the second-largest region at $25.10 billion in 2025. - The report also highlights strong growth in the Middle East and Africa at 7.8% CAGR and South America at $5.70 billion in 2025. - The report lists key companies including Abbott Laboratories, Pfizer, Medtronic and Johnson & Johnson. - Abbott received FDA approval in March 2025 for its Proclaim XR closed-loop spinal cord stimulator with AI-adaptive algorithms. - Pfizer announced a $1.8 billion licensing agreement in January 2025 for a non-opioid sodium channel inhibitor. - Medtronic launched the Inceptiv closed-loop recharge-free neurostimulator in Europe in October 2024.

Between the lines: - The forecast reflects a broader industry reset as regulators, payers and investors favor non-addictive options over legacy opioid models. - Settlement pressure from U.S. opioid litigation, which exceeds $50 billion, continues to weigh on opioid-focused players. - ESG-focused investors are steering capital toward multimodal analgesia and device-based chronic pain treatments. - Digital therapeutics are becoming more credible as AI-assisted tapering and biometric monitoring gain clinical and payer interest. - The report suggests closed-loop neuromodulation could become one of the market’s biggest growth engines over the next several years.

What’s next: - More reimbursement support could accelerate adoption of interventional procedures, wearable devices and prescription digital therapeutics. - The report expects AI-powered precision pain management to play a larger role by 2030. - It also forecasts that closed-loop neuromodulation platforms will create an $8 billion-plus addressable opportunity by 2032. - Broader use of multimodal care could continue shifting revenue away from opioid monotherapy and toward integrated treatment models. - More information is available in the full report.